AI-Driven Therapeutics for Chronic Hepatitis B Functional Cure

Livera is developing dual-function therapeutics to silence HBV RNA, reduce viral antigen burden, and reawaken the body’s antiviral immune response.

Advancing Innovation in Drug Discovery

Through AI-driven discovery and dual-function siRNA design, we aim to transform chronic hepatitis B treatment from long-term viral suppression toward functional cure by combining viral RNA silencing with immune reactivation.

Leadership

Board of Directors

Investors

Leadership Team

Li Ke

CEO

Xincan Qiu

CSO

Yuhang Wang

VP of Chemistry

Yizhong Wang

Head of Drug Delivery

Renhai Huang

Head of AI Platform

Xiaolin Gan

Business Lead

Xiaoting Tang

Clinical Lead